Evolent Health stock sits 51.86 percent below its 52-week high

Published on 10/08/2026 at 16:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sixteen analysts set a USD 5.96 average target. Evolent Health stock costs EUR 3.56 on October 8, 2026, minus 3.52 percent versus EUR 3.69.

Key points in brief

Evolent Health stock stood 51.86 percent below its USD 8.33 52-week high on October 8, 2026.
Lang & Schwarz quoted Evolent Health at EUR 3.56, down 3.52 percent versus the EUR 3.69 prior close.
Revenue reached USD 652.50 million in the second quarter of 2026, up 46.90 percent year over year.
Sixteen analysts tracked by MarketBeat set a USD 5.96 average 12-month price target.

EVH, US30050B1017, Illustration mit AI erstellt.

Evolent Health stock stood 51.86 percent below its USD 8.33 52-week high on October 8, 2026, while Lang & Schwarz quoted the shares at EUR 3.56 at 4:30 p.m. CEST. The primary-market quote was USD 4.01 at 10:34 a.m. EDT, putting the stock at USD 4.32 below its yearly high of USD 8.33.

Three target changes shaped the picture

MarketBeat reported that Citigroup cut its target from USD 6.75 to USD 6.00 on August 10, 2026, while retaining a buy rating. The same report said Truist Financial reduced its target from USD 7.00 to USD 6.00 on August 12, 2026, and kept a hold rating.

On August 17, 2026, TD Cowen raised its target from USD 5.00 to USD 6.00 and assigned a buy rating, according to MarketBeat. The sequence leaves the published targets clustered at USD 6.00 even as the market quote remains below that level.

What does the earnings base show?

Yahoo Finance reported revenue of USD 652.50 million in the second quarter of 2026, up 46.90 percent from the same quarter a year earlier. The report also said revenue exceeded analyst expectations by 9.40 percent, giving investors a quantified comparison beyond the stock's daily move.

The standardized financial data show a consolidated net loss of USD 28.36 million and diluted earnings per share of minus USD 0.25 for the second quarter of 2026. Operating margin was minus 1.00 percent in that period, so the revenue expansion has not yet translated into positive quarterly earnings.

Next date and trading reference

ToAlpha lists November 5, 2026 as Evolent Health's next earnings date, with a consensus earnings-per-share estimate of minus USD 0.05 for the coming quarter. The date gives the market a defined checkpoint for testing whether revenue growth can coexist with improving profitability.

Lang & Schwarz quoted Evolent Health at EUR 3.56 on October 8, 2026 at 4:30 p.m. CEST, down 3.52 percent versus the EUR 3.69 prior close of October 7, 2026. The continuously updated real-time quote of Evolent Health stock shows the further course of trading.